Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPH2102 maintenance in elderly acute myeloid leukemia in first complete remission
2012-001594-93Phase 2Completed
- Sponsor
- Innate Pharma
- Start
- Sep 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute myeloid leukemia (AML) comparing IPH2102 maintenance with Placebo maintenance (2 arms). Primary endpoint: Leukemia-free survival. Started Sep 2012; status: completed.
02
Drugs
lirilumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2012-001594-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001594-93.